Quotes 5-day view Delayed Nasdaq
01/21/2021
01/22/2021
01/25/2021
01/26/2021
01/27/2021
Date
2.69(c)
2.85(c)
2.83(c)
3.06(c)
2.78(c)
Last
222 868
436 188
405 274
1 812 055
648 187
Volume
-2.89% +5.95% -0.70% +8.13% -9.15% Change
Sales 2018
1,67 M - -
Net income 2018
-10,8 M - -
Net cash position 2018
5,46 M - -
P/E ratio 2018
-1,22x
Yield 2018
-
Sales 2019
1,58 M - -
Net income 2019
-3,89 M - -
Net cash position 2019
9,68 M - -
P/E ratio 2019
-0,50x
Yield 2019
-
Capitalization
24,6 M 24,6 M -
EV / Sales 2018
5,19x
EV / Sales 2019
-3,83x
Nbr of Employees
12
Free-Float
84,1%
Akers Biosciences, Inc. develops, manufactures, and supplies point-of-care screening and testing products designed to bring health-related information directly to the patient or clinician. The Company’s product offerings focus on delivering diagnostic assistance in a variety of healthcare fields/specialties, including diagnostic rapid manual point-of-care tests for the detection of allergic reactions to Heparin...
All news about AKERS BIOSCIENCES, INC.
01/25 AKERS BIOSCIENCES : Submission of Matters to a Vote of Security Holders (form 8-..AQ
2020 AKERS BIOSCIENCES INVESTOR ALERT BY : Kahn Swick & Foti, LLC Investigates Merge..BU
2020 AKERS BIOSCIENCES : ' Proposed Merger Partner MyMD Pharmaceuticals Announces Iss..BU
2020 AKERS BIOSCIENCES, INC. : Change in Directors or Principal Officers (form 8-K)AQ
2020 AKERS BIOSCIENCES, INC. : Other Events, Financial Statements and Exhibits (form ..AQ
2020 AKERS BIOSCIENCES, INC. : Other Events, Financial Statements and Exhibits (form ..AQ
2020 REMINDER : Akers Biosciences Schedules Conference Call to Discuss Merger with My..BU
2020 AKERS BIOSCIENCES INVESTOR ALERT BY : Kahn Swick & Foti, LLC Investigates Merge..BU
2020 AKERS BIOSCIENCES : Management's Discussion and Analysis of Financial Condition ..AQ
2020 AKERS BIOSCIENCES, INC. : Other Events (form 8-K)AQ
2020 AKERS BIOSCIENCES : Entry into a Material Definitive Agreement, Unregistered Sal..AQ
2020 AKERS BIOSCIENCES, INC. : Entry into a Material Definitive Agreement, Unregister..AQ
2020 AKERS MERGER INVESTIGATION : Halper Sadeh LLP Announces Investigation Into Wheth..BU
2020 Akers Biosciences, MyMD Pharmaceuticals Ink Merger Agreement MT
2020 AKERS BIOSCIENCES : and MyMD Pharmaceuticals Sign Definitive Merger AgreementBU
News in other languages on AKERS BIOSCIENCES, INC.
- No features available -
Chart AKERS BIOSCIENCES, INC.
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends AKERS BIOSCIENCES, INC.
Short Term Mid-Term Long Term Trends Bullish Bearish Bearish
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Canada
Deutschland
España
France
Italia
Schweiz (DE)
United Kingdom
Report
